Featured News

The Celiac Disease Foundation, a trusted partner in optimizing patient recruitment and retention, announces the launch of its iRecruitCeliac platform, which brings together solutions to accelerate enrollment in clinical trials for celiac disease and comorbid conditions.

DDW 2023 showcased some of the latest research and innovations in celiac disease. These included promising early results from four investigational medications currently being tested for the treatment of celiac disease, as well as CDF research conducted in partnership with Takeda and Adelphi Real World.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.

The Celiac Disease Foundation is pleased to announce it will provide patient recruitment and eligibility screening for Anokion’s phase 1b/2 clinical trial for KAN-101.

The PROACTIVE Celiac Study is a phase 2 clinical trial testing the safety and effects of the investigational medication PRV-015.

Consider joining the LILY Study, a phase 1 clinical trial for people with celiac disease investigating DONQ52, a new potential celiac disease treatment.

Join the Solutions for Celiac Study where you get access to blood testing, symptom tracking tools, and celiac specialists focused on your disease.

Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.

There are more exciting opportunities than ever before to participate in celiac disease clinical trials. Researchers are making groundbreaking progress in the race for better treatments with promising new drug candidates.